Skip to main content

Table 2 Univariable analysis for the risk factors of EBV and CMV infections post-transplantation

From: Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

Parameters EBV-DNAemia EBV-associated disease CMV-DNAemia CMV-associated disease
Gender P=0.679 P=0.125 P=0.385 P=0.844
Female vs male
Patient age P=0.687 P=0.881 P=0.137 P=0.694
< 35 vs ≥ 35 years
EBV serostatus P=0.067 P=0.502 -- --
D−/R+ vs other
CMV serostatus -- -- P=0.573 P=0.797
D−/R+ vs other
CR status at transplant P=0.163 P=1.000 *P=0.025 P=0.455
≥ CR2 vs CR1
ATG use in the conditioning# *P<0.001 *P=0.036 *P<0.001 P=0.985
ATG vs no ATG
Sorafenib pre-transplant P=0.349 P=0.727 P=0.085 P=0.296
Use vs no use
Sorafenib post-transplant P=0.853 P=0.628 P=0.892 P=0.702
Sorafenib vs control
aGVHD& P=0.417 P=0.196 *P=0.004 *P=0.023
cGVHD& P=0.891 P=0.190 P=0.248 P=0.120
  1. Abbreviations: EBV Epstein-Barr virus, D donor, R recipient, CMV cytomegalovirus, CR complete remission, CR2 second CR, CR1 first CR, ATG antithymocyte immunoglobulin; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD. *P<0.05. #All patients undergoing haploidentical donor (HID)/HLA-matched unrelated donor (MUD) transplants received ATG as GVHD prophylaxis, and none of those undergoing HLA-matched sibling donor (MSD) transplants received ATG as GVHD prophylaxis. Considering there was collinearity between transplant modality (HID/MUD vs MSD) and ATG use in the conditioning (ATG vs no ATG), we only included ATG use in the conditioning in the analysis of risk factors for EBV/CMV infections. &Time-dependent covariate